
Liquid Biopsy Market - forecast to 2033 : By BIOMARKER TYPE (ctDNA, CTCs, Exosomes, Others), APPLICATION (Oncology, NIPT, Transplant Diagnostics, Others), TECHNOLOGY (Next-Generation Sequencing, Polymerase Chain Reaction, Droplet Digital PCR, Circulating
Description
Liquid Biopsy Market - forecast to 2033 : By BIOMARKER TYPE (ctDNA, CTCs, Exosomes, Others), APPLICATION (Oncology, NIPT, Transplant Diagnostics, Others), TECHNOLOGY (Next-Generation Sequencing, Polymerase Chain Reaction, Droplet Digital PCR, Circulating Tumor Cells, Others), SAMPLE TYPE (Blood, Urine, Saliva, Others), CANCER TYPE (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Other Cancers), END USER (Hospitals, Research Institutes, Others), CLINICAL APPLICATION (Early Cancer Detection, Treatment Monitoring, Recurrence Monitoring, Therapy Selection), and Region
The Liquid Biopsy Market refers to the rapidly evolving field of non-invasive diagnostic and monitoring procedures that utilize fluids such as blood, urine, or saliva to detect and monitor diseases. These procedures offer a minimally invasive alternative to traditional tissue biopsies, providing real-time, dynamic information about disease progression, response to treatment, and potential relapse.
The Liquid Biopsy Market Market size was USD 6 Billion in 2023, and it is anticipated to grow to over 15.87 Billion by 2033, at a CAGR of over 10.6% during the forecast period
The Liquid Biopsy Market is significantly driven by its innovative technological advancements, which continuously enhance diagnostic techniques and expand their applications. Central to the growth of this market is the role of liquid biopsies in personalized medicine, offering tailored treatment plans based on individual patient profiles. Their non-invasive nature enhances patient comfort and compliance, while their ability to provide real-time monitoring of disease progression and treatment response facilitates more effective disease management. Although primarily used in oncology, the potential applications of liquid biopsies in areas such as prenatal testing and organ transplant monitoring further fuel market expansion.
Key Trends:
- Non-Invasive Procedures: Growing preference for non-invasive diagnostic procedures over traditional surgical biopsies.
- Technological Advancements: Rapid advancements in sequencing technologies and bioinformatics are driving the market growth.
- Rising Cancer Prevalence: Increasing global incidence of cancer is fueling the demand for early and efficient diagnostic methods.
- Personalized Medicine: Liquid biopsy is becoming a crucial tool in the development of personalized treatment plans for cancer patients.
- Reimbursement & Regulatory Policies: Favorable reimbursement policies and regulatory approvals are propelling the market expansion.
- Non-Invasive Procedure: The ability to detect cancer mutations without invasive surgery is a major driver for the market.
- Technological Advancements: Rapid advancements in sequencing technologies and bioinformatics are propelling the market forward.
- Early Detection: Liquid biopsies can detect cancer at an early stage, improving patient prognosis.
- Personalized Medicine: Liquid biopsies can help tailor treatments to individual patients, a growing trend in healthcare.
- Rising Prevalence of Cancer: The increasing global incidence of cancer is driving demand for better diagnostic tools, including liquid biopsies.
- Regulatory Challenges: The liquid biopsy market faces stringent regulatory requirements for product approval, which can slow down market growth.
- High Cost of Procedures: The high cost associated with liquid biopsy tests can limit their adoption, particularly in developing regions.
- Lack of Awareness: There is a lack of awareness about the benefits of liquid biopsy tests, particularly among patients in developing countries.
- Limited Reimbursement Policies: In many regions, the reimbursement policies for liquid biopsy tests are not well-defined, which can deter patients from opting for these tests.
- Technical Limitations: There are still technical limitations and challenges associated with liquid biopsy tests, including sensitivity and specificity issues, which can affect their adoption.
Biomarker Type (Ctdna, Ctcs, Exosomes, Others), Application (Oncology, Nipt, Transplant Diagnostics, Others), Technology (Next-Generation Sequencing, Polymerase Chain Reaction, Droplet Digital Pcr, Circulating Tumor Cells, Others), Sample Type (Blood, Urine, Saliva, Others), Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Other Cancers), End User (Hospitals, Research Institutes, Others), Clinical Application (Early Cancer Detection, Treatment Monitoring, Recurrence Monitoring, Therapy Selection), And Region
Key Players:
The Liquefied Petroleum Gas Market includes players such as Guardant Health, Biocept, Myriad Genetics, QIAGEN, Roche, Illumina, Bio-Rad Laboratories, Thermo Fisher Scientific, Genomic Health, MDxHealth, Exact Sciences, Inivata, Natera, Biodesix, PGD, NeoGenomics, Freenome, GRAIL, and Trovagene, among others.
Value Chain Analysis:
The value chain analysis for the Liquid Biopsy Market can be delineated into five critical stages: Raw Material Procurement, Research and Development (R&D), Product Approval, Large Scale Manufacturing, and Sales and Marketing. Each of these stages plays a pivotal role in ensuring the seamless progression from conceptualization to market delivery of Liquid Biopsy products.
- Raw Material Procurement: Identify sources of raw materials, assess their availability, quality, and sustainability. Understanding market dynamics, pricing trends, and potential risks associated with sourcing materials is crucial. This includes evaluating suppliers for reliability, negotiating contracts to ensure cost-effectiveness, and ensuring compliance with regulatory standards for medical-grade materials.
- Research and Development (R&D): R&D focuses on market analysis, trend forecasting, feasibility studies, and conducting experiments to develop new products or enhance existing ones. This stage involves extensive laboratory research, clinical trials, and collaboration with academic institutions and industry experts to innovate and refine biopsy technologies. It also includes intellectual property management to protect proprietary innovations.
- Product Approval: Understanding legal requirements, industry regulations, and certification processes, testing products for safety, efficacy, and environmental impact. This stage necessitates rigorous clinical validation, submission of comprehensive documentation to regulatory bodies such as the FDA or EMA, and navigating the approval processes to obtain necessary certifications and licenses. Ensuring compliance with global standards is essential for market entry and credibility.
- Large Scale Manufacturing: Optimizing production processes, improving efficiency, and reducing costs. This involves process engineering, automation technologies, and supply chain management to enhance productivity and quality. The focus is on scaling up from pilot production to full-scale manufacturing while maintaining stringent quality control measures. This stage also includes logistics planning to ensure timely delivery of products to various markets.
- Sales and Marketing: Understanding customer needs, market trends, and competitive landscape, market segmentation, consumer behavior analysis, and branding strategies. This stage encompasses the development of marketing campaigns, sales strategies, and distribution channels to effectively reach target audiences. It also involves building relationships with key stakeholders such as healthcare providers, insurers, and policymakers to drive market adoption and growth. Continuous market feedback is essential to refine and adapt strategies for sustained success.
- Estimates and forecast the overall market size for the total market, across type, application, and region
- Detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling
- Identify factors influencing market growth and challenges, opportunities, drivers, and restraints
- Identify factors that could limit company participation in identified international markets to help properly calibrate market share expectations and growth rates
- Trace and evaluate key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities
- Thoroughly analyze smaller market segments strategically, focusing on their potential, individual patterns of growth, and impact on the overall market
- To thoroughly outline the competitive landscape within the market, including an assessment of business and corporate strategies, aimed at monitoring and dissecting competitive advancements
- Identify the primary market participants, based on their business objectives, regional footprint, product offerings, and strategic initiatives.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Table of Contents
350 Pages
- 1.0: MARKET DEFINITION
- 1.1: MARKET SEGMENTATION
- 1.2: REGIONAL COVERAGE
- 1.3: KEY COMPANY PROFILES
- 1.4: DATA SNAPSHOT
- 2.0: SUMMARY
- 2.1: KEY OPINION LEADERS
- 2.2: KEY HIGHLIGHTS BY BIOMARKER TYPE
- 2.3: KEY HIGHLIGHTS BY APPLICATION
- 2.4: KEY HIGHLIGHTS BY TECHNOLOGY
- 2.5: KEY HIGHLIGHTS BY SAMPLE TYPE
- 2.6: KEY HIGHLIGHTS BY CANCER TYPE
- 2.7: KEY HIGHLIGHTS BY END USER
- 2.8: KEY HIGHLIGHTS BY CLINICAL APPLICATION
- 2.9: KEY HIGHLIGHTS BY REGION
- 3.0: MARKET ATTRACTIVENESS ANALYSIS BY BIOMARKER TYPE
- 3.1: MARKET ATTRACTIVENESS ANALYSIS BY APPLICATION
- 3.2: MARKET ATTRACTIVENESS ANALYSIS BY TECHNOLOGY
- 3.3: MARKET ATTRACTIVENESS ANALYSIS BY SAMPLE TYPE
- 3.4: MARKET ATTRACTIVENESS ANALYSIS BY CANCER TYPE
- 3.5: MARKET ATTRACTIVENESS ANALYSIS BY END USER
- 3.6: MARKET ATTRACTIVENESS ANALYSIS BY CLINICAL APPLICATION
- 3.7: MARKET ATTRACTIVENESS ANALYSIS BY REGION
- 4.0: MARKET TRENDS
- 4.1: MARKET DRIVERS
- 4.2: MARKET OPPORTUNITIES
- 4.3: MARKET RESTRAINTS
- 4.4: MARKET THREATS
- 4.5: IMPACT ANALYSIS
- 5.0: PORTERS FIVE FORCES
- 5.1: ANSOFF MATRIX
- 5.2: PESTLE ANALYSIS
- 5.3: VALUE CHAIN ANALYSIS
- 6.0: IMPACT OF COVID-19 ON MARKET
- 7.0: IMPACT OF RUSSIA-UKRAINE WAR
- 8.0: PARENT MARKET ANALYSIS
- 8.1: REGULATORY LANDSCAPE
- 8.2: PRICING ANALYSIS
- 8.3: DEMAND SUPPLY ANALYSIS
- 8.4: CONSUMER BUYING INTEREST
- 8.5: SUPPLY CHAIN ANALYSIS
- 8.6: COMPETITION PRODUCT ANALYSIS BY MANUFACTURER
- 8.7: TECHNOLOGICAL ADVANCEMENTS
- 8.8: RECENT DEVELOPMENTS
- 8.9: CASE STUDIES
- 9.0: BIOMARKER TYPE OVERVIEW
- 9.1: MARKET SIZE AND FORECAST – BY BIOMARKER TYPE
- 9.2: CIRCULATING TUMOR DNA (CTDNA) OVERVIEW
- 9.3: CIRCULATING TUMOR DNA (CTDNA) BY REGION
- 9.4: CIRCULATING TUMOR CELLS (CTCS) OVERVIEW
- 9.5: CIRCULATING TUMOR CELLS (CTCS) BY REGION
- 9.6: EXOSOMES OVERVIEW
- 9.7: EXOSOMES BY REGION
- 9.8: OTHERS OVERVIEW
- 9.9: OTHERS BY REGION
- 10.0: APPLICATION OVERVIEW
- 10.1: MARKET SIZE AND FORECAST – BY APPLICATION
- 10.2: ONCOLOGY OVERVIEW
- 10.3: ONCOLOGY BY REGION
- 10.4: NON-INVASIVE PRENATAL TESTING (NIPT) OVERVIEW
- 10.5: NON-INVASIVE PRENATAL TESTING (NIPT) BY REGION
- 10.6: TRANSPLANT DIAGNOSTICS OVERVIEW
- 10.7: TRANSPLANT DIAGNOSTICS BY REGION
- 10.8: OTHERS OVERVIEW
- 10.9: OTHERS BY REGION
- 11.0: TECHNOLOGY OVERVIEW
- 11.1: MARKET SIZE AND FORECAST – BY TECHNOLOGY
- 11.2: NEXT-GENERATION SEQUENCING OVERVIEW
- 11.3: NEXT-GENERATION SEQUENCING BY REGION
- 11.4: POLYMERASE CHAIN REACTION OVERVIEW
- 11.5: POLYMERASE CHAIN REACTION BY REGION
- 11.6: DROPLET DIGITAL PCR OVERVIEW
- 11.7: DROPLET DIGITAL PCR BY REGION
- 11.8: CIRCULATING TUMOR CELLS OVERVIEW
- 11.9: CIRCULATING TUMOR CELLS BY REGION
- 11.10: OTHERS OVERVIEW
- 11.11: OTHERS BY REGION
- 12.0: SAMPLE TYPE OVERVIEW
- 12.1: MARKET SIZE AND FORECAST – BY SAMPLE TYPE
- 12.2: BLOOD OVERVIEW
- 12.3: BLOOD BY REGION
- 12.4: URINE OVERVIEW
- 12.5: URINE BY REGION
- 12.6: SALIVA OVERVIEW
- 12.7: SALIVA BY REGION
- 12.8: OTHERS OVERVIEW
- 12.9: OTHERS BY REGION
- 13.0: CANCER TYPE OVERVIEW
- 13.1: MARKET SIZE AND FORECAST – BY CANCER TYPE
- 13.2: LUNG CANCER OVERVIEW
- 13.3: LUNG CANCER BY REGION
- 13.4: BREAST CANCER OVERVIEW
- 13.5: BREAST CANCER BY REGION
- 13.6: COLORECTAL CANCER OVERVIEW
- 13.7: COLORECTAL CANCER BY REGION
- 13.8: PROSTATE CANCER OVERVIEW
- 13.9: PROSTATE CANCER BY REGION
- 13.10: OTHER CANCERS OVERVIEW
- 13.11: OTHER CANCERS BY REGION
- 14.0: END USER OVERVIEW
- 14.1: MARKET SIZE AND FORECAST – BY END USER
- 14.2: HOSPITALS OVERVIEW
- 14.3: HOSPITALS BY REGION
- 14.4: RESEARCH INSTITUTES OVERVIEW
- 14.5: RESEARCH INSTITUTES BY REGION
- 14.6: OTHERS OVERVIEW
- 14.7: OTHERS BY REGION
- 15.0: CLINICAL APPLICATION OVERVIEW
- 15.1: MARKET SIZE AND FORECAST – BY CLINICAL APPLICATION
- 15.2: EARLY CANCER DETECTION OVERVIEW
- 15.3: EARLY CANCER DETECTION BY REGION
- 15.4: TREATMENT MONITORING OVERVIEW
- 15.5: TREATMENT MONITORING BY REGION
- 15.6: RECURRENCE MONITORING OVERVIEW
- 15.7: RECURRENCE MONITORING BY REGION
- 15.8: THERAPY SELECTION OVERVIEW
- 15.9: THERAPY SELECTION BY REGION
- 16.0: REGION OVERVIEW
- 16.1: MARKET SIZE AND FORECAST - BY REGION
- 16.2: NORTH AMERICA OVERVIEW
- 16.3: NORTH AMERICA BY COUNTRY
- 16.4: UNITED STATES OVERVIEW
- 16.5: CANADA OVERVIEW
- 17.0: COMPETITION OVERVIEW
- 17.1: MARKET SHARE ANALYSIS
- 17.2: MARKET REVENUE BY KEY COMPANIES
- 17.3: MARKET POSITIONING
- 17.4: VENDORS BENCHMARKING
- 17.5: STRATEGY BENCHMARKING
- 17.6: STRATEGY BENCHMARKING
- 18.0: Guardant Health
- 18.1: Guardant Health
- 18.2: Guardant Health
- 18.3: Guardant Health
- 18.4: Guardant Health
- 18.5: Biocept
- 18.6: Biocept
- 18.7: Biocept
- 18.8: Biocept
- 18.9: Biocept
- 18.10: Myriad Genetics
- 18.11: Myriad Genetics
- 18.12: Myriad Genetics
- 18.13: Myriad Genetics
- 18.14: Myriad Genetics
- 18.15: Roche
- 18.16: Roche
- 18.17: Roche
- 18.18: Roche
- 18.19: Roche
- 18.20: Illumina
- 18.21: Illumina
- 18.22: Illumina
- 18.23: Illumina
- 18.24: Illumina
- 18.25: Bio-Rad Laboratories
- 18.26: Bio-Rad Laboratories
- 18.27: Bio-Rad Laboratories
- 18.28: Bio-Rad Laboratories
- 18.29: Bio-Rad Laboratories
- 18.30: Thermo Fisher Scientific
- 18.31: Thermo Fisher Scientific
- 18.32: Thermo Fisher Scientific
- 18.33: Thermo Fisher Scientific
- 18.34: Thermo Fisher Scientific
- 18.35: Genomic Health
- 18.36: Genomic Health
- 18.37: Genomic Health
- 18.38: Genomic Health
- 18.39: Genomic Health
- 18.40: Menarini Silicon Biosystems
- 18.41: Menarini Silicon Biosystems
- 18.42: Menarini Silicon Biosystems
- 18.43: Menarini Silicon Biosystems
- 18.44: Menarini Silicon Biosystems
- 18.45: MDxHealth
- 18.46: MDxHealth
- 18.47: MDxHealth
- 18.48: MDxHealth
- 18.49: MDxHealth
- 18.50: Exact Sciences
- 18.51: Exact Sciences
- 18.52: Exact Sciences
- 18.53: Exact Sciences
- 18.54: Exact Sciences
- 18.55: Inivata
- 18.56: Inivata
- 18.57: Inivata
- 18.58: Inivata
- 18.59: Inivata
- 18.60: Natera
- 18.61: Natera
- 18.62: Natera
- 18.63: Natera
- 18.64: Natera
- 18.65: Biodesix
- 18.66: Biodesix
- 18.67: Biodesix
- 18.68: Biodesix
- 18.69: Biodesix
- 18.70: Personal Genome Diagnostics
- 18.71: Personal Genome Diagnostics
- 18.72: Personal Genome Diagnostics
- 18.73: Personal Genome Diagnostics
- 18.74: Personal Genome Diagnostics
- 18.75: NeoGenomics
- 18.76: NeoGenomics
- 18.77: NeoGenomics
- 18.78: NeoGenomics
- 18.79: NeoGenomics
- 18.80: Freenome
- 18.81: Freenome
- 18.82: Freenome
- 18.83: Freenome
- 18.84: Freenome
- 18.85: Trovagene
- 18.86: Trovagene
- 18.87: Trovagene
- 18.88: Trovagene
- 18.89: Trovagene
- 256})
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.